

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
6B	7-9	Early Entry into Prenatal Care	Percentage of prenatal care patients who entered prenatal care during their first trimester	Women seen for prenatal care during the year	Women beginning prenatal care at the health center or with a referral provider, or with the another prenatal care provider during their first trimester	None	no eCQM	73.8%	None	None	<ul style="list-style-type: none"> • Trimester of entry is based on last menstrual period (vs. conception) <ul style="list-style-type: none"> • 1st trimester is through end of 13th week • 2nd trimester is start of 14th week to end of 27th week • 3rd trimester starts at 28th week • If you referred women to other providers for all their prenatal care, report the trimester of their first prenatal visit with the other provider in Column A • Patient self-report of trimester of entry is permitted • Include women who began prenatal care in 2018 and delivered in 2019 • To determine the appropriate age group, use the woman's age on June 30th of the reporting year
6B	10	Childhood Immunization Status	Percentage of children 2 years of age who were fully immunized by their second birthday	Children who turn 2 years of age during the measurement period and who had a medical visit during the measurement period	Children who were fully immunized by their second birthday. A child is fully immunized if s/he has been vaccinated or there is documented evidence of history of illness, a seropositive test result, or an allergic reaction for ALL of the following: 4 diphtheria, tetanus, and acellular pertussis (DTaP); 3 polio (IPV), 1 measles, mumps, and rubella (MMR); 3 H influenza type B (HiB); 3 Hepatitis B (Hep B); 1 chicken pox (VZV); 4 pneumococcal conjugate (PCV); 1 Hepatitis A (Hep A); 2 or 3 rotavirus (RV); and 2 influenza (flu) vaccines	Patients who were in hospice care during the measurement period	CMS117v7	39.4%	None	None	<ul style="list-style-type: none"> • Record must list the dates of all immunizations and names of immunization agents • Good faith efforts do not meet the measurement standard, including: <ul style="list-style-type: none"> • Failure to bring patient in • Refusal for personal or religious reasons • Be sure to assess patients: <ul style="list-style-type: none"> • Who turned two during the year (do not include other ages), even if they were not seen before they turned two <ul style="list-style-type: none"> • Whose only medical visit is for acute or urgent care

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
6B	11	Cervical Cancer Screening	Percentage of women 21*–64 years of age who were screened for cervical cancer(*Use age 23 as the initial age to include in the assessment)	Women 23 through 64 years of age with a medical visit during the measurement period	Women with one or more screenings for cervical cancer using either of the following criteria: * Women age 23-64 who had cervical cytology during the measurement period or the 2 years prior to the measurement period for women who are at least 21 years old at the time of the test * Women age 30-64 who had cervical cytology/human papillomavirus (HPV) co-testing performed during the measurement period or the 4 prior years to the measurement period	<ul style="list-style-type: none"> • Women who had a hysterectomy with no residual cervix or a congenital absence of cervix • Women who were in hospice care during the measurement period 	CMS124v7	56%		None	<ul style="list-style-type: none"> • Documentation in the medical record must include date of test, who performed it, and test result • Do not count in the numerator: <ul style="list-style-type: none"> • Referrals to third parties without documentation of results • Statements from patient that it was done—without documentation • Refusal of patient to have the test • Include women in the evaluation of this measure if they had any medical visit during the year, regardless of the nature of the visit • Include patients who were provided obstetrics / gynecological services elsewhere

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
6B	12	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient medical visit and who had: <ul style="list-style-type: none"> evidence of height, weight, and body mass index (BMI) percentile documentation and who had documentation of counseling for nutrition and who had documentation of counseling for physical activity during the measurement period 	Patients 3 through 17 years of age with at least one medical visit during the measurement period	Patients who had: <ul style="list-style-type: none"> Their BMI percentile (not just BMI or height and weight) recorded during the measurement period AND Who had documentation of counseling for nutrition during the measurement period AND Who had documentation of counseling for physical activity during during the measurement period 	<ul style="list-style-type: none"> Patients who have a diagnosis of pregnancy during the measurement period Patients who were in hospice care during the measurement period 	CMS155v7	69.2%	None	<ul style="list-style-type: none"> eCQM denominator is limited to outpatient visits with a primary care physician or obstetrician / gynecologist. UDS includes children seen by nurse practitioners and physician assistants Numerator BMI, nutrition, and activity are reported separately in the eCQM, but combined in the UDS 	<ul style="list-style-type: none"> Include children and adolescents in the evaluation of this measure if they had any medical visit with the health center during the year Do not count well-child visits as automatically meeting the measurement standard

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
6B	13	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan	Percentage of patients aged 18 years and older with BMI documented during the most recent visit or within the 12 months prior to that visit and when the BMI is outside of normal parameters, a follow-up plan is documented during the visit or during the previous 12 months of that visit	Patients 18 years of age or older on the date of the visit with at least one medical visit during the measurement period	Patients with a documented BMI (not just height and weight) during the most recent visit in the measurement period or during the previous 12 months of that visit, AND when the BMI is outside of normal parameters, a follow-up plan is documented during the visit or during the previous 12 months of the current visit. Normal parameters: Age 18 years and older BMI was greater than or equal to 18.5 and less than 25 kg/m ²	<ul style="list-style-type: none"> • Patients who are pregnant during the measurement period • Patients receiving palliative care during or prior to the visit • Patients who refuse measurement of height and/or weight, or refuse follow-up during the visit • Patients with a documented medical reason during the visit or within 12 months of the visit, including: <ul style="list-style-type: none"> • Elderly patients for whom weight reduction/ weight gain would complicate other underlying health conditions • Patients in an urgent or emergent medical situation where time is of the essence and to delay treatment would jeopardize the patient's health status 	CMS69v7	70.1%	None	None	<ul style="list-style-type: none"> • Include adults in the evaluation of this measure if they had any medical visit during the year, regardless of the nature of the visit • If more than one BMI is reported during the measurement period, use the most recent BMI to determine if the performance has been met.

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
6B	14a	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	Percentage of patients aged 18 and older who were screened for tobacco use one or more times within 24 months and who received cessation counseling intervention if defined as a tobacco user	Patients aged 18 years and older seen for at least two medical visits in the measurement period or at least one preventive medical visit during the measurement period	Patients who were screened for tobacco use at least once within 24 months before the end of the measurement period, AND who received tobacco cessation intervention if identified as a tobacco user	Documentation of medical reason(s) for not screening for tobacco use or for not providing tobacco cessation intervention (e.g., limited life expectancy, other medical reason)	CMS138v7	88.1%	None	<ul style="list-style-type: none"> Denominator population and numerator are reported separately in the eCQM, but combined in the UDS 	<ul style="list-style-type: none"> Cessation counseling intervention for a tobacco user must occur at or following the most recent screening and before the end of the measurement year. Count in the numerator both patients with a negative screening result AND those with a positive screening who had cessation services provided Include all forms of tobacco, but exclude e-cigarettes, in the screening Include patients who receive tobacco cessation intervention by any provider, including: <ul style="list-style-type: none"> Received tobacco use cessation counseling services, or Received an order (a prescription or a recommendation to purchase an over the counter [OTC] product) for a tobacco use cessation medication, or Are on (using) a tobacco use cessation agent
6B	16	Use of Appropriate Medications for Asthma	Percentage of patients 5-64 years of age who were identified as having persistent asthma and who were appropriately ordered medication during the measurement period	Patients age 5 through 64 years with persistent asthma with a medical visit during the measurement period	Patients who were ordered at least one prescription for a preferred therapy during the measurement period	<ul style="list-style-type: none"> Patients with a diagnosis of emphysema, chronic obstructive pulmonary disease, obstructive chronic bronchitis, cystic fibrosis, or acute respiratory failure that overlaps the measurement period 	CMS126v5	86.6%	None	Note: eCQM specifications for this measure have not been updated.	<ul style="list-style-type: none"> Preferred therapy includes patients who: Received a prescription for or were using an inhaled corticosteroid, or received a prescription for or were using an acceptable pharmacological agent, specifically inhaled steroid combinations, anti-asthmatic combinations, antibody inhibitor, leukotriene modifiers, mast cell stabilizers, or methylxanthines Query system to identify only those patients with persistent asthma (not mild or intermittent asthma)

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
6B	17a	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	<p>Percentage of the following patients at high risk of cardiovascular events aged 21 years and older who were prescribed or were on statin therapy during the measurement period</p> <ul style="list-style-type: none"> • Patients 21 years of age or older previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); or • Patients 21 years of age or older who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level greater than or equal to 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; or • Patients 40 through 75 years of age with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL. 	<p>Patients 21 years of age and older with who have an active diagnosis of ASCVD or ever had a fasting or direct laboratory result of LDL-C greater than or equal to 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; or patients 40 through 75 years of age with Type 1 or Type 2 diabetes and with an LDL-C result 70-189 mg/dL recorded as the highest fasting or direct laboratory test result in the measurement year or the 2 years prior; with a medical visit during the measurement period</p>	<p>Patients who are actively using or who received an order (prescription) for statin therapy at any point during the measurement period</p>	<ul style="list-style-type: none"> • Patients who have a diagnosis of pregnancy • Patients who are breastfeeding. • Patients who have a diagnosis of rhabdomyolysis. • Patients with adverse effect, allergy, or intolerance to statin medication. • Patients who are receiving palliative care. • Patients with active liver disease or hepatic disease or insufficiency. • Patients with end-stage renal disease (ESRD). • For patients 40 through 75 years of age with diabetes who have the most recent fasting or direct LDL-C laboratory test result less than 70 mg/dL and are not taking statin therapy. 	CMS347v2	n/a	<ul style="list-style-type: none"> • New measure for CY2019. Replaces previous CAD measure. 	<ul style="list-style-type: none"> • Current statin therapy use (including statin medication samples provided to patients) must be documented in the patient's current medication list or ordered during the measurement period. • Do not count other cholesterol lowering medications as meeting the measurement standard—only statin therapy meets the measurement standard. • Ensure patients are not counted in the denominator more than once. Once a patient meets one set of denominator criteria (check from first listed in Measure Description to last), he/she is included and further risk checks are not needed. • Intensity of statin therapy or lifestyle modification coaching is not being assessed for this measure—only prescription of any statin therapy. 	

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
6B	18	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet	Percentage of patients aged 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), or who had a coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCIs) in the 12 months prior to the measurement period, or who had an active diagnosis of IVD during the measurement period, and who had documentation of use of aspirin or another antiplatelet during the measurement period	Patients 18 years of age and older with a medical visit during the measurement period and who had an AMI, CABG, or PCI in the 12 months prior to the measurement period or who had a diagnosis of IVD overlapping the measurement period	Patients who had an active medication of aspirin or another antiplatelet during the measurement period	<ul style="list-style-type: none"> • Patients who had documentation of use of anticoagulant medications overlapping the measurement period • Patients who were in hospice care during the measurement period 	CMS164v7	80.9%	None	None	<ul style="list-style-type: none"> • Include in the numerator patients who received a prescription for, were given, or were using aspirin or another antiplatelet drug

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
6B	19	Colorectal Cancer Screening	Percentage of adults 50–75 years of age who had appropriate screening for colorectal cancer	Patients 50 through 75 years of age with a medical visit during the measurement period	Patients with one or more screenings for colorectal cancer. Appropriate screenings are defined by any one of the following: <ul style="list-style-type: none"> • Fecal occult blood test (FOBT) during the measurement period • Fecal immunochemical test (FIT)-deoxyribonucleic acid (DNA) during the measurement period or the 2 years prior to the measurement period • Flexible sigmoidoscopy during the measurement period or the 4 years prior to the measurement period • Computerized tomography (CT) colonography during the measurement period or the 4 years prior to the measurement period • Colonoscopy during the measurement period or the 9 years prior to the measurement period 	<ul style="list-style-type: none"> • Patients with a diagnosis of colorectal cancer or history of total colectomy • Patients who were in hospice care during the measurement period 	CMS130v7	44.1%	<ul style="list-style-type: none"> • Do not count digital rectal exam (DRE), FOBT tests performed in an office setting or performed on a sample collected via DRE. 	None	<ul style="list-style-type: none"> • There are two FOBT test options: Guaiac fecal occult blood test (gFOBT) and the immunochemical-based fecal occult blood test (iFOBT - commonly known as a FIT test)
6B	20	HIV Linkage to Care	Percentage of patients newly diagnosed with HIV who were seen for follow-up treatment within 90 days of diagnosis	Patients first diagnosed with HIV by the health center between October 1 of prior year through September 30 of the current measurement year and who had at least one medical visit during the measurement period or prior year	Newly diagnosed HIV patients that received treatment within 90 days of diagnosis. Include patients who: <ul style="list-style-type: none"> • Were newly diagnosed by your health center providers, and • Had a medical visit with your health center provider who initiates treatment for HIV, or • Had a visit with a referral resource who initiates treatment for HIV 	None	<u>no eCQM</u>	85.5%	None	None	<ul style="list-style-type: none"> • Only include patients in the denominator who have never before been diagnosed with HIV anywhere • Note that the identification of patients for this measure crosses years and may include prior year patients • To confirm HIV diagnosis, patient must receive a reactive initial HIV test confirmed by a positive supplemental HIV (blood) test • Medical treatment must be initiated within 90 days of HIV diagnosis (not just a referral made, education provided, or retesting conducted)

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
6B	21	Preventive Care and Screening: Screening for Depression and Follow-Up Plan	Percentage of patients aged 12 years and older screened for depression on the date of the visit using an age-appropriate standardized depression screening tool, and if positive, a follow-up plan is documented on the date of the positive screen	Patients aged 12 years and older with at least one medical visit during the measurement period	Patients screened for depression on the date of the visit using an age-appropriate standardized tool and, if screened positive for depression, a follow-up plan is documented on the date of the positive screen	<ul style="list-style-type: none"> • Patients with an active diagnosis for depression or a diagnosis of bipolar disorder • Patients who refuse to participate • Patients who are in urgent or emergent situations where time is of the essence and to delay treatment would jeopardize the patient's health status • Patients whose functional capacity or motivation to improve may impact the accuracy of results of standardized assessment tools 	CMS2v8	70.6%	Do not count a PHQ-9 screening that follows a positive PHQ-2 screening during the measurement period as meeting the measurement standard for a follow-up plan to a positive depression screening.	None	<ul style="list-style-type: none"> • Use the most recent screening results • Patients who are in ongoing treatment for depression are not included in the denominator • Remember to count in the numerator both patients with a negative screening result AND those with a positive screening who had a follow-up plan • Do not count patients who are re-screened as meeting the measurement standard as a follow-up plan to a positive screen
6B	22	Dental Sealants for Children between 6-9 Years	Percentage of children, age 6–9 years, at moderate to high risk for caries who received a sealant on a first permanent molar during the measurement period	Children 6 through 9 years of age with an oral assessment or comprehensive or periodic oral evaluation dental visit and are at moderate to high risk for caries in the measurement period	Children who received a sealant on a permanent first molar tooth during the measurement period	<ul style="list-style-type: none"> • Children for whom all first permanent molars are non-sealable (i.e., molars are either decayed, filled, currently sealed, or unerupted/missing) 	CMS277v0	52.8%	None	Note: Although measure title is age 6 through 9 years, draft e-CQM reflects age 5 through 9 years —Health centers should continue to use age 6 through 9 years, as measure steward intended	<ul style="list-style-type: none"> • Include patients who had a dental visit with the health center or with another dental provider through a paid referral • You must determine risk level, not count all dental patients of this age range in universe • Risk level is a finding at the patient-level, not a population-based factor such as low socio-economic status • If risk level or tooth placement is unknown for patients, pull a sample to help identify this information

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
7	1a-1d	Low Birth Weight	Percentage of babies of health center prenatal care patients born whose birth weight was below normal (less than 2,500 grams)	Babies born during measurement period to prenatal care patients	Babies born with a birth weight below normal (under 2,500 grams)	• Still-births or miscarriages	no eCQM	8%	None	None	<ul style="list-style-type: none"> Report babies according to their birth weight in grams: <ul style="list-style-type: none"> Very low (Column 1b) = Less than 1,500 grams Low (Column 1c) = 1,500 grams through 2,499 grams Normal (Column 1d) = 2,500 grams or greater The higher the percentage of babies born below normal birth weight, the poorer the outcome Report race and ethnicity of mother and baby separately Report all live births separately by birth weight Report mothers in prenatal program and their babies, even if prenatal care or delivery was done by a non-health center provider Prenatal Women ≠ Deliveries ≠ Birth Outcomes Review outcomes against overall patient population mix
7	2a-2c	Controlling High Blood Pressure	Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (less than 140/90 mmHg) during the measurement period	Patients 18 through 85 years of age who had a diagnosis of essential hypertension within the first six months of the measurement period or any time prior to the measurement period with a medical visit during the period	Patients whose blood pressure at the most recent visit is adequately controlled (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg) during the measurement period	<ul style="list-style-type: none"> Patients with evidence of end-stage renal disease (ESRD), dialysis, or renal transplant before or during the measurement period Patients with a diagnosis of pregnancy during the measurement period Patients who were in hospice care during the measurement period 	CMS165v7	63.3%	None	None	<ul style="list-style-type: none"> Do not include patients in the denominator if initial diagnosis of hypertension was made after June 30th of measurement period Include patients with no test during the year in the denominator, but do not include in the numerator <ul style="list-style-type: none"> Report them in Columns 2a and 2b, but not in Column 2c Include blood pressure readings taken at any visit type at the health center as long as the result is from the most recent visit Review crude prevalence rates by taking number with hypertension by race and ethnicity (Table 7) divided by total patients of same race and ethnicity (Table 3B)

Table	Line	UDS Measure Name	Brief Description	Denominator (Universe)	Numerator	Exclusions or Exceptions	eCQM # (for 2019 Report)	2018 National Average	Major Differences from 2018 to 2019	Major Differences from UDS to eCQM	Reminders
7	3a-3f	Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)	Percentage of patients 18–75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period	Patients 18 through 75 years of age with diabetes with a medical visit during the measurement period	Patients whose most recent HbA1c level during the measurement year is greater than 9.0 percent or who had no test conducted during the measurement period	<ul style="list-style-type: none"> Patients who were in hospice care during the measurement period 	CMS122v7	32.9%	None	None	<ul style="list-style-type: none"> Include patients with an active diagnosis of Type 1 or Type 2 diabetes Include patients with active diabetes regardless of when first diagnosed Do not include patients with a diagnosis of secondary diabetes due to another condition (such as gestational diabetes) in the denominator Note: The higher the percentage of patients with Hba1c of 9.0 percent or over, the poorer the clinical performance Review crude prevalence rates by taking number with diabetes by race and ethnicity (Table 7) divided by total patients of same race and ethnicity (Table 3B)

Web link reference: <https://ecqi.healthit.gov/eligible-professional/eligible-clinician-ecqms/2019-performance-period-ep/ec-ecqms>